Tarsus Pharmaceuticals
TARS
73.61
-0.50
-0.67%
Tarsus Pharmaceuticals
US · TARS
#2389 by market cap
Listed 2020
73.61
-0.50
-0.67%
Live - 5344 symbols - heartbeat 197s ago
· 2026-10-08 07:00
Pre-market
73.41
-0.27%
After-hours
73.61
0.00%
- Market cap
- 3.44B
- P/E (TTM)i
- -68.79
- P/Bi
- 9.93
- EPSi
- -1.59
- Div yieldi
- 0.00%
- 52W posi
- 52%
Reader sentiment
Are you bullish or bearish on TARS?
Anonymous reader poll. Unscientific, not investment advice.
Analyst consensus 10 analysts
Buy
Avg price target
100.11 +36.0%
Price target rangecurrent 73.61
Low88.00
Avg100.11
High116.00
Buy 100%
Hold 0%
Sell 0%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-02 | Oppenheimer | -- | BUY | 100.00 |
| 2026-09-24 | Goldman Sachs | -- | BUY | 116.00 |
| 2026-09-16 | Barclays | -- | BUY | 110.00 |
| 2026-09-08 | Jefferies | -- | BUY | 105.00 |
| 2026-08-12 | William Blair | -- | BUY | -- |
| 2026-08-12 | Oppenheimer | -- | BUY | 100.00 |
| 2026-08-11 | Mizuho Securities | -- | BUY | 100.00 |
| 2026-08-08 | LifeSci Capital | -- | BUY | 104.00 |
| 2026-08-07 | LifeSci Capital | -- | BUY | 104.00 |
| 2026-08-07 | Mizuho Securities | -- | BUY | 100.00 |
| 2026-08-07 | H.C. Wainwright | -- | BUY | 88.00 |
| 2026-08-04 | Mizuho Securities | -- | BUY | 98.00 |
| 2026-07-31 | Mizuho Securities | -- | BUY | 98.00 |
| 2026-07-21 | Guggenheim | -- | BUY | 89.00 |
| 2026-07-21 | Oppenheimer | -- | BUY | 97.00 |
| 2026-07-14 | William Blair | -- | BUY | -- |
| 2026-07-14 | Mizuho Securities | -- | BUY | 100.00 |
| 2026-07-14 | Guggenheim | -- | BUY | 90.00 |
| 2026-07-14 | Oppenheimer | -- | BUY | 97.00 |
| 2026-07-13 | LifeSci Capital | -- | BUY | 95.00 |
| 2026-07-13 | Guggenheim | -- | BUY | 90.00 |
| 2026-07-10 | Barclays | -- | BUY | 100.00 |
| 2026-07-09 | William Blair | -- | BUY | -- |
| 2026-07-09 | Mizuho Securities | -- | BUY | 100.00 |
| 2026-07-09 | H.C. Wainwright | -- | BUY | 88.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Hold
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
1
■ Upgrades■ Downgrades
- 1 upgrade vs 0 downgrades among tracked analyst rating changes.
- Most recent: Goldman Sachs moved from Hold to Buy on 2026-09-24.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-09-24 | Goldman Sachs | HOLD → BUY | 116.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-06 | -- | ±11.25% | +6.59% (in line) |
| 2026/Q1 | 2026-05-06 | After close | ±13.47% | -1.24% (in line) |
| 2025/Q4 | 2026-02-23 | After close | ±14.71% | +7.79% (in line) |
| 2025/Q3 | 2025-11-04 | After close | ±12.86% | -4.62% (in line) |
| 2025/Q2 | 2025-08-06 | After close | ±17.32% | +15.15% (in line) |
| 2025/Q1 | 2025-05-01 | After close | ±14.67% | -5.84% (in line) |
| 2024/Q4 | 2025-02-25 | -- | ±16.97% | -9.33% (in line) |
| 2024/Q3 | 2024-11-13 | After close | ±23.27% | +0.31% (in line) |
| 2024/Q2 | 2024-08-08 | After close | ±16.52% | +13.72% (in line) |
| 2024/Q1 | 2024-05-08 | After close | ±18.63% | -8.86% (in line) |
| 2023/Q4 | 2024-02-27 | -- | ±14.92% | -3.44% (in line) |
| 2023/Q3 | 2023-11-09 | After close | -- | +12.20% |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-08 07:00:14 · For reference only, not investment advice and not tailored to your situation.